AnnoRoad Gene Technology (Beijing) Co., Ltd. (AnnoRoad) saw its Hong Kong IPO prospectus expire on September 25th, six months after its submission on March 25th. China Construction Bank International and Guotai Junan International served as joint sponsors for the listing.

According to the prospectus, AnnoRoad is a company focused on IVD medical devices and multi-omics life science research services based on molecular diagnostics, and is also an industry pioneer specializing in NGS-based prenatal testing IVD products. The company's clinical sequencing solutions include self-produced gene sequencing-based IVD testing kits, gene sequencers and bioinformatics analysis software, as well as supporting technical support and laboratory design services.